Latest Strategy Changes News

Following a recent unitholder meeting, One Managed Investment Funds Limited has initiated the orderly liquidation of the Fat Prophets Global Property Fund’s portfolio, signaling a significant transition for investors.

Uscom Limited reports a 56% increase in cash on hand to $2.17 million for Q2 2024, driven by strategic moves in China and new product regulatory approvals.

Golden Horse Minerals Ltd posted a CAD 413,000 net cash outflow from operating activities in the December 2024 quarter, while maintaining a robust cash balance of CAD 13.37 million. The company’s cash burn reflects ongoing exploration and evaluation investments.

Golden Horse Minerals has successfully listed on the ASX, raising A$18 million to fund exploration across a consolidated 130km strike in Western Australia's Southern Cross Greenstone Belt. The company is gearing up for a major drilling campaign at the historic Hopes Hill gold mine.

Coda Minerals has significantly enhanced the economic outlook of its Elizabeth Creek Copper-Cobalt Project, with a pre-tax NPV7 rising to $1.18 billion and a post-tax NPV7 increase of 57% to $802 million. The company also secured $5.1 million in fresh capital to accelerate exploration and drilling activities in 2025.

IVE Group Limited has scheduled its half-year financial results release for February 24, 2025, alongside a notable governance change with Paul Selig moving from Executive to Non-Executive Director.

Patriot Lithium Limited has made significant strides in acquiring and exploring copper projects in Zambia while navigating complex negotiations for its key Gorman Lithium Project in Canada.

Pacific Current Group reports a 6.1% increase in total Funds Under Management to A$30 billion as of December 31, 2024, despite a decline in USD-denominated assets and exits from two boutique managers.

Careteq Limited reports solid progress in integrating its Embedded Health Solutions with HMR Referrals, alongside a 14% revenue increase and improved cash flow in Q2 FY25.

Osteopore Limited reports a robust 27% year-over-year revenue increase despite operational headwinds, underpinned by new collaborations in stem cell therapies and expanded market access in Brazil and Singapore.

Mesoblast has secured FDA approval for Ryoncil®, the first mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in children, while raising A$260 million to accelerate clinical trials and commercial rollout.

QEM Limited has marked significant progress in its Julia Creek Vanadium and Energy Project, securing key government approvals and raising $2.76 million to advance development and environmental studies.